The Europe Tissue Diagnostics Market would witness market growth of 8.7% CAGR during the forecast period (2023-2030).
The adoption of tissue diagnostics is not limited to traditional pathology laboratories. It spans various healthcare settings, including hospitals, academic research institutions, reference laboratories, and diagnostic centers. The demand for accurate and reliable diagnostic information has led to integrating tissue diagnostics into various medical specialties, such as oncology, infectious diseases, autoimmune disorders, and neurological conditions.
Furthermore, the applications of tissue diagnostics are broad and encompass various medical fields. Oncology is one of the primary areas where it has been substantially impacted. Tumor characterization, grading, and determination of biomarker expression play a crucial role in cancer diagnosis and treatment planning. It helps identify specific genetic mutations, expression patterns, and tumor heterogeneity, facilitating the selection of targeted therapies and personalized treatment regimens.
Prostate cancer incidence rates in Europe are substantial, with the disease representing a major public health concern. The aging population, lifestyle factors, and genetic predisposition contribute to the high prevalence of prostate cancer. The escalating incidence of diagnosed cases necessitates more effective and dependable tissue diagnostics to enable timely identification and well-informed therapeutic choices. As per the data from the European Commission, it is estimated that, in EU-27 countries in 2020, prostate cancer accounted for 23.2% of all new cancer cases (excluding non-melanoma skin cancers) diagnosed in men and 9.9% of all deaths due to cancer in men. This made it the most frequently occurring cancer in men and the third cause of cancer death in men–after lung and colorectal cancers. Thus, rising breast and prostate cancer cases in Europe will help in the growth of the regional market.
The Germany market dominated the Europe Tissue Diagnostics Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $631.8 million by 2030. The UK market is exhibiting a CAGR of 7.7% during (2023 - 2030). Additionally, The France market would experience a CAGR of 9.5% during (2023 - 2030).
Free Valuable Insights: The Global Tissue Diagnostics Market will Hit $10.1 Billion by 2030, at a CAGR of 9.1%
Based on Product, the market is segmented into Consumables (Antibodies, Kits, Reagents, Probes), and Instruments (Slide-staining Systems, Scanners, Tissue Processing Systems, Others). Based on Technology, the market is segmented into Immunohistochemistry, In Situ Hybridization, Digital Pathology & Workflow, and Special Staining. Based on Disease Type, the market is segmented into Breast Cancer, Lymphoma, Prostate Cancer, Gastric Cancer, Non-small Cell Lung Cancer, and Others. Based on End User, the market is segmented into Hospitals, Research Laboratories, Pharmaceutical Organizations, Contract Research Organizations (CROs), and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
By Product
By Technology
By Disease Type
By End User
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
